Evidence map›Paper›PMID 40422185›Full record

ArticleCells2025

Effects of Cisplatin on the Radiation Response and DNA Damage Markers in Peripheral Blood Lymphocytes Ex Vivo.

Sebastian Zahnreich, Aisha Bhatti, Barea Ahmad, Sophia Drabke, Justus Kaufmann, Heinz Schmidberger

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sebastian ZahnreichDepartment of Radiation Oncology and Radiation Therapy, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0001-8365-3258
Aisha BhattiDepartment of Radiation Oncology and Radiation Therapy, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Barea AhmadDepartment of Radiation Oncology and Radiation Therapy, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Sophia DrabkeDepartment of Radiation Oncology and Radiation Therapy, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Justus KaufmannDepartment of Radiation Oncology and Radiation Therapy, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0003-0189-3499
Heinz SchmidbergerDepartment of Radiation Oncology and Radiation Therapy, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.

Funding

German Federal Ministry of Education and Research 02NUK084A
6 · The paper itself

Abstract

Platinum-based radiochemotherapy is associated with hematologic side effects, impacting patient outcomes. However, the clinical mechanisms of cisplatin and its interaction with ionizing radiation (IR), including in biodosimetry for radiotherapy, have not yet been fully clarified. For this purpose, healthy donors' peripheral blood lymphocytes (PBLs) were pretreated with cisplatin in a pulse (1-4 h) or continuous (24 h) regimen followed by X-rays. DNA damage was assessed as DNA double-strand breaks using repair foci of γH2AX and 53BP1 after 0.5 h and 24 h in G1 PBLs and a proliferation-based cytokinesis-block micronucleus assay. Additionally, cell death and proliferation activity were measured. Unlike a 1 h pulse, a 24 h cisplatin pretreatment caused a concentration-dependent increase in cisplatin-induced foci while decreasing IR-induced foci, especially 24 h after irradiation. This was accompanied by increased apoptosis, with cisplatin and IR having additive effects. Both genotoxins alone caused a dose-dependent increase in micronuclei, while cisplatin significantly reduced binuclear cells, especially after the 24 h treatment, leading to lower micronuclei frequencies post-irradiation. Our results show that prolonged cisplatin exposure, even at low concentrations, impacts the vitality and division activity of PBLs, with significantly stronger effects post-irradiation. This has major implications and must be considered for the detection of DNA damage-associated biomarkers in PBLs used in clinical prediction or biodosimetry during radiotherapy.

Indexed as

CisplatinDNA DamageLymphocytesAdultApoptosisBiomarkersCell ProliferationDNA Breaks, Double-StrandedFemaleHistonesHumansMaleMicronucleus TestsRadiation, IonizingX-RaysBiomarkersCisplatinHistonesapoptosisbiodosimetrycisplatinDNA damageionizing radiationlymphopeniamicronucleiperipheral blood lymphocytesradiotherapy

Identifiers

PMID40422185
PMCPMC12109825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.